Vardenafil

Formulary

Volumn 38, Issue 3, 2003, Pages 131-148

  Coleman, Craig I ^a   Carabino, Jana M ^a   Vergara, Cunegundo M ^b   Wang, Fei ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b University of Connecticut ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ALUMINUM OXIDE; CIMETIDINE; CYTOCHROME P450; DIGOXIN; GLYCERYL TRINITRATE; MAGNESIUM HYDROXIDE; NIFEDIPINE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; RANITIDINE; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL;

CLINICAL TRIAL; COLOR VISION DEFECT; DIABETES MELLITUS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEMODYNAMICS; HUMAN; LIVER METABOLISM; PROSTATE SURGERY; PROSTATECTOMY; REVIEW; RHINITIS; SIDE EFFECT;

EID: 0038078808     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (37)

1. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151:54-61.
3. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000;163:460-3.
4. AACE clinical practice guidelines for the evaluation and treatment of male sexual dysfunction. Endocr Pract 1998;4(4):219-35.
5. Langtry H, Markham A. Sildenafil. A review of its use in erectile dysfunction. Drugs 1999;57:967-89.
6. Azarbal B, Mirocha J, Shah PK, Cercek B, Kaul S. Adverse cardiovascular events associated with the use of Viagra [abstract]. J Am Coll Cardiol 2000; 35(suppl A):553A-554A.
7. Cohen JS. Comparison of FDA reports of patient deaths associated with sildenafil and with injectable alprostadil. Ann Pharmacother 2001;35:285-7.
8. Padma-Nathan H, Giuliano F. Oral drug therapy for erectile dysfunction. Urol Clin North Am 2001;28:321-34.
9. RxList. The top 200 prescriptions for 2001 by number of US prescriptions dispensed. Available at: http://www.rxlist.com/top200.htm. Accessed August 12, 2002.
10. PharmWeb. Bayer AG press release. First release of vardenafil Phase III pivotal study data. December 12, 2001. Available at: http://www.pharmiweb.com/news/pressrelease/pressrelease.asp?PRID=167. Accessed August 14, 2002.
11. Kim NN, Huang Y, Goldstein I, Bischoff E,Traish AM. Inhibition of cyclic GMP hydrolysis in human corpus cavernosum smooth muscle cells by vardenafil, a novel, selective phosphodiesterase type 5 inhibitor. Life Sci 2001;69:2249-56.
12. Sweetman S (Ed), Martindale: The Complete Drug Reference. London: Pharmaceutical Press. Electronic version, MICROMEDEX, Greenwood Village, Colorado, Edition expires 3/2/2003.
13. Saenz de Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001;13:282-90.
14. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002;14 (suppl 1):S57-64.
15. Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001;40:181-90.
16. Klotz T, Sachse R, Heidrich A, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001;19:32-9.
17. Steidle CP, Feldman R, Lettieri J, Agarwal V, Segerson T. Pharmacokinetics of vardenafil (a new selective PDE5 inhibitor) in the elderly and subgroup data on efficacy and safety in elderly patients with erectile dysfunction [abstract]. J Am Geriatr Soc 2001;49(4):S103.
18. Klotz T, Pollock M, Rohde G, Bauer RJ. Effect of renal impairment on the single-dose pharmacokinetics of vardenafil 20 mg, a selective PDE5 inhibitor, for the treatment of erectile dysfunction. Paper presented at: 2002 Spring Research Forum of the American College of Clinical Pharmacy (ACCP); April 7-10, 2002; Savannah, GA.
19. Viagra [package insert]. New York, NY: Pfizer Inc; 2001.
20. Porst H, Rosen R, Padma-Nathan H, et al. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001;13:192-9.
21. Hellstrom WJG, Gittelman MC, Shapiro J, et al. Vardenafil improved erectile function in men with a broad range of erectile dysfunction etiologies and severities: a phase III trial. Paper presented at the Annual Meeting of the Sexual Medicine Society of North American Urological Association; June 2-7, 2001; Anaheim, CA. Abstract 924.
22. Goldstein I, Young J, Fischer J, et al. Vardenafil, a new highly selective PDE5 inhibitor, improves erectile function in patients with diabetes mellitus [abstract]. Diabetes 2001;50(suppl 2). Abstract 456P.
23. Brock G, Padma-Nathan H, Seger M. Efficacy and tolerability of vardenafil in males with erectile dysfunction following radical prostatectomy. Paper presented at the 17th Annual Congress of the European Association of Urology; February 23-26, 2002; Birmingham, England.
24. Porst H, Padma-Nathan H, Thibonnier M, Eardley I. Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in men with erectile dysfunction on antihypertensive therapy. Paper presented at the 17th Annual Congress of the European Association of Urology; February 23-26, 2002; Birmingham, England.
25. Donatucci C, Eardley I, McVary KT, et al. Vardenafil improves erectile function regardless of etiology or baseline severity in men with erectile dysfunction. Paper presented at the 97th Annual Scientific Meeting of the American Urological Association (AUA); May 25-28, 2002; Orlando, FL. Abstract 715.
26. Donatucci C, Karlin G, Goldfischer E, Cohen S, Thibonnier M. Influence of age on the efficacy and safety of vardenafil, a novel phosphodiesterase-5 inhibitor, for the treatment of erectile dysfunction. Paper presented at the Annual Scientific Meeting of the American Geriatrics Society; May 8-12, 2002; Washington DC.
27. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822-30.
28. Fugl-Meyer A, Lodnert G, Branholm I, Fugl-Meyer KS. On life satisfaction in males erectile dysfunction. Int J Impot Res 1997;9(3):141-8.
29. Porst H, Schmidt AC, and The Vardenafil Study Group. Vardenafil improved erectile function regardless of baseline severity, etiology, and hypertensive medications in phase II trial. Paper presented at the Annual Meeting of the Sexual Medicine Society of North America; December 7-9, 2001;Charleston, SC. Abstract 21.
30. Wagner G, Mulhall J. Pathophysiology and diagnosis of male erectile dysfunction. Br J Urol Int 2001;88(suppl 3):3-10.
31. Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA. Cardiovascular effects of sildenafil during exercise in men with known or probable coronary artery disease. A randomized crossover trial. JAMA 2002; 287:719-25.
32. Mazzu A, Nicholls A, Zinny M. Vardenafil, a new selective PDE-5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged male subjects. Paper presented at the Annual Meeting of the Sexual Medicine Society of North America; December 7-9 2001; Charleston, SC. Abstract 19.
33. Rohde G, Jordaan PJ. Influence of vardenafil on blood pressure and pharmacokinetics in hypertensive patients on nifedipine therapy. Paper presented at the 2002 Spring Practice and Research Forum of the American College of Clinical Pharmacy (ACCP); April 7-10, 2002; Savannah, GA.
34. Rohde G, Bauer RJ, Unger S, Ahr G, Wensing G, Kuhlmann J. Vardenafil, a new selective PDE5 inhibitor, produces no interaction with digoxin [abstract]. Pharmacother 2001;21:1254.
35. Rohde G, Wensing G, Unger S. The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, are minimally affected by coadministration with cimetidine or ranitidine [abstract]. Pharmacother 2001;21:1254.
36. Rohde G, Wensing G. The pharmacokinetics of vardenafil, a new selective PDE5 inhibitor, are not affected by the antacid, Maalox 70 [abstract]. Pharmacother 2001;21:1254.
37. Drug Topics Red Book 2002. Viagra (sildenafil). Thomson Medical Economics, Montvale, NJ.